Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings or view top-rated stocks.

2 brokers have issued 1 year target prices for Ironwood Pharmaceuticals' shares. Their IRWD share price targets range from $19.00 to $22.00. On average, they predict the company's stock price to reach $20.67 in the next year. This suggests a possible upside of 96.3% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.

Ironwood Pharmaceuticals' stock was trading at $12.39 at the start of the year. Since then, IRWD stock has decreased by 15.0% and is now trading at $10.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our IRWD earnings forecast.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by $0.05. The biotechnology company had revenue of $113.74 million for the quarter, compared to the consensus estimate of $112.90 million. Ironwood Pharmaceuticals had a positive trailing twelve-month return on equity of 112.29% and a negative net margin of 220.24%. The firm's revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS.

ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS), SPDR S&P Biotech ETF (XBI) and Pacer US Small Cap Cash Cows 100 ETF (CALF).

Ironwood Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.00 million-$450.00 million, compared to the consensus revenue estimate of $441.42 million.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (4.59%), Victory Capital Management Inc. (2.82%), Armistice Capital LLC (2.21%), Adage Capital Partners GP L.L.C. (1.58%), Jacobs Levy Equity Management Inc. (1.52%) and Jupiter Asset Management Ltd. (1.42%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Sravan Kumar Emany, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.